Maze Therapeutics, Inc. (NASDAQ: MAZE) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 10.12% | Shs Outstand | 55.35M | Perf Week | -0.97% |
| Market Cap | 1.53B | Forward P/E | - | EPS next Y | -3.22 | Insider Trans | -4.43% | Shs Float | 15.98M | Perf Month | -14.65% |
| Enterprise Value | 1.23B | PEG | - | EPS next Q | - | Inst Own | 120.25% | Short Float | 9.98% | Perf Quarter | 2.53% |
| Income | -131.00M | P/S | 74.49 | EPS this Y | - | Inst Trans | - | Short Ratio | 8.23 | Perf Half Y | -40.66% |
| Sales | 0.00 | P/B | 4.47 | EPS next Y | -17.96% | ROA | -29.20% | Short Interest | 5.53M | Perf YTD | -33.36% |
| Book/sh | 6.18 | P/C | 4.34 | EPS next 5Y | - | ROE | -36.63% | 52W High | 53.65 -48.54% | Perf Year | 85.30% |
| Cash/sh | 6.36 | P/FCF | - | EPS past 3/5Y | - | ROIC | -33.24% | 52W Low | 12.81 115.53% | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 92.04% | Volatility | 5.17% 5.36% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 67.62 | EPS Y/Y TTM | -3351.93% | Oper. Margin | -670.25% | ATR (14) | 1.49 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 17.88 | Sales Y/Y TTM | - | Profit Margin | -612.71% | RSI (14) | 47.30 | Recom | 1.86 |
| Dividend Gr. 3/5Y | - | Current Ratio | 17.88 | EPS Q/Q | 60.87% | SMA20 | -3.73% | Beta | 1.06 | Target Price | 80.50 |
| Payout | 0.00% | Debt/Eq | 0.05 | Sales Q/Q | - | SMA50 | 1.06% | Rel Volume | 0.64 | Prev Close | 27.33 |
| Employees | 141 | LT Debt/Eq | 0.05 | Earnings | Aug 11 | SMA200 | -20.09% | Avg Volume | 576.31K | Price | 27.61 |
| IPO Date | Jan 31, 2025 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 21.98% 88.24% | Net Debt/EBITDA | 1.15 | Volume | 367,352 | Change | 1.02% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Apr-14-26 | Reiterated | Truist Securities | Buy | $68 → $64 |
| Mar-17-26 | Reiterated | Truist Financial | $68 | |
| Mar-10-26 | Initiated | Mizuho | Outperform | $97 |
| Jan-16-26 | Reiterated | BTIG | Buy | $30 → $46 |
| Dec-19-25 | Reiterated | Guggenheim | Buy | $34 → $46 |
| Dec-04-25 | Initiated | Wells Fargo | Overweight | $55 |
| Dec-03-25 | Reiterated | HC Wainwright & Co. | Buy | $60 |
| Nov-13-25 | Initiated | Raymond James | Strong Buy | $48 |
| Sep-15-25 | Reiterated | Guggenheim | Buy | $34 |
| Sep-02-25 | Initiated | BTIG | Buy | $30 |
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | |
|---|---|---|---|---|---|
| Total Revenue | 0 | 168 | 0 | 0 | |
| Cost of Goods Sold Incl. D&A | 2 | 0 | 0 | 0 | |
| Gross Profit | -2 | 168 | 0 | 0 | |
| Selling, General and Administrative Excl. Other | 34 | 26 | 25 | 23 | |
| Research and Development | 108 | 83 | 74 | 88 | |
| Other Operating Expense | -2 | 1 | 0 | 0 | |
| Operating Income | -143 | 58 | -99 | -111 | |
| Interest Expense | 0 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | |
| Non-Operating Income (Expense) | 12 | -4 | -2 | -4 | |
| Net Income Before Taxes | -131 | 53 | -100 | -115 | |
| Income Taxes | 0 | 1 | 0 | 0 | |
| Consolidated Net Income | -131 | 52 | -100 | -115 | |
| Net Income From Continuing Operations | -131 | 52 | -100 | -115 | |
| Net Income | -131 | 52 | -100 | -115 | |
| EPS (Recurring) | -3.05 | 0.08 | -2.29 | -2.63 | |
| EPS (Basic, Before Extraordinaries) | -3.05 | 0.08 | -2.29 | -2.63 | |
| EPS (Diluted) | -3.05 | 0.08 | -2.29 | -2.63 | |
| EBITDA | -129 | 57 | -96 | -111 | |
| Other After Tax Adjustments | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | |
| Gross Margin | — | 100.00 | — | — | |
| Operating Margin | — | 34.52 | — | — | |
| Net Margin | — | 30.95 | — | — | |
| Shares Outstanding | 43 | 44 | 44 | 44 | |
| Market Capitalization | 1,781 | — | — | — | |
| Operating Lease Expense | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Dandekar Atul | CSBO | Jul 29 '26 | Sale | 27.34 | 7,500 | 205,031 | 26,250 | Jul 31 |
| Dandekar Atul | CSBO | Jul 29 '26 | Option Exercise | 10.42 | 7,500 | 78,150 | 33,750 | Jul 31 |
| Bernstein Harold | President, R&D & CMO | Jul 01 '26 | Sale | 29.90 | 14,609 | 436,864 | 0 | Jul 02 |
| Coloma Jason V | Chief Executive Officer | Jul 01 '26 | Sale | 29.98 | 34,501 | 1,034,253 | 23,337 | Jul 02 |
| Bernstein Harold | President, R&D & CMO | Jul 01 '26 | Option Exercise | 10.42 | 14,609 | 152,226 | 14,609 | Jul 02 |
| Dandekar Atul | CSBO | Jun 29 '26 | Option Exercise | 10.42 | 7,500 | 78,150 | 33,750 | Jul 01 |
| Dandekar Atul | CSBO | Jun 29 '26 | Sale | 28.02 | 7,500 | 210,150 | 26,250 | Jul 01 |
| Coloma Jason V | Chief Executive Officer | Jun 23 '26 | Sale | 26.05 | 23,865 | 621,674 | 319,079 | Jun 24 |
| Coloma Jason V | Chief Executive Officer | Jun 22 '26 | Sale | 26.00 | 3,993 | 103,821 | 25,930 | Jun 24 |
| Coloma Jason V | Chief Executive Officer | Jun 01 '26 | Sale | 26.20 | 6,643 | 174,048 | 27,970 | Jun 03 |
| Bernstein Harold | President, R&D & CMO | Jun 01 '26 | Option Exercise | 10.42 | 14,853 | 154,768 | 14,853 | Jun 03 |
| Bernstein Harold | President, R&D & CMO | Jun 01 '26 | Sale | 25.66 | 14,853 | 381,112 | 0 | Jun 03 |
| Dandekar Atul | CSBO | May 29 '26 | Option Exercise | 10.42 | 7,500 | 78,150 | 32,308 | Jun 02 |
| Dandekar Atul | CSBO | May 29 '26 | Sale | 26.34 | 7,500 | 197,554 | 24,808 | Jun 02 |
| Coloma Jason V | Chief Executive Officer | May 26 '26 | Sale | 26.02 | 25,582 | 665,516 | 350,987 | May 27 |